Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

9FIZ

Structure of the F13 protein (mutant A295E) of Vaccinia virus

Summary for 9FIZ
Entry DOI10.2210/pdb9fiz/pdb
DescriptorEnvelope phospholipase OPG057, CITRIC ACID, GLYCEROL, ... (4 entities in total)
Functional Keywordspoxvirus, phospholipase d, vaccinia virus, viral protein
Biological sourceVaccinia virus Western Reserve
Total number of polymer chains1
Total formula weight43714.18
Authors
Vernuccio, R.,Guardado-Calvo, P. (deposition date: 2024-05-30, release date: 2025-03-12, Last modification date: 2025-03-19)
Primary citationVernuccio, R.,Martinez Leon, A.,Poojari, C.S.,Buchrieser, J.,Selverian, C.N.,Jaleta, Y.,Meola, A.,Guivel-Benhassine, F.,Porrot, F.,Haouz, A.,Chevreuil, M.,Raynal, B.,Mercer, J.,Simon-Loriere, E.,Chandran, K.,Schwartz, O.,Hub, J.S.,Guardado-Calvo, P.
Structural insights into tecovirimat antiviral activity and poxvirus resistance.
Nat Microbiol, 10:734-748, 2025
Cited by
PubMed Abstract: Mpox is a zoonotic disease endemic to Central and West Africa. Since 2022, two human-adapted monkeypox virus (MPXV) strains have caused large outbreaks outside these regions. Tecovirimat is the most widely used drug to treat mpox. It blocks viral egress by targeting the viral phospholipase F13; however, the structural details are unknown, and mutations in the F13 gene can result in resistance against tecovirimat, raising public health concerns. Here we report the structure of an F13 homodimer using X-ray crystallography, both alone (2.1 Å) and in complex with tecovirimat (2.6 Å). Combined with molecular dynamics simulations and dimerization assays, we show that tecovirimat acts as a molecular glue that promotes dimerization of the phospholipase. Tecovirimat resistance mutations identified in clinical MPXV isolates map to the F13 dimer interface and prevent drug-induced dimerization in solution and in cells. These findings explain how tecovirimat works, allow for better monitoring of resistant MPXV strains and pave the way for developing more potent and resilient therapeutics.
PubMed: 39939832
DOI: 10.1038/s41564-025-01936-6
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (2.6 Å)
Structure validation

236620

数据于2025-05-28公开中

PDB statisticsPDBj update infoContact PDBjnumon